Lexicon Pharmaceuticals Incorporated Company Profile - Aug 25, 2011 by WrightReports

VIEWS: 16 PAGES: 11

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Lexicon Pharmaceuticals Incorporated
                                                                                         440 Wheelers Farms Road
                                                                                         Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:CBNN                                Key Data

   Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company focused on       Ticker:
   the discovery and development of treatments for human disease. Lexicon uses its         LXRX
   gene knockout technologies and an integrated platform of medical technologies to
   study the physiological and behavioral functions of almost 5,000 genes in mice and      2010 Sales:
   assessed the utility of the proteins encoded by the corresponding human genes as
                                                                                           4,908,000
   drug targets. The Company has conducted Phase II clinical trials of two of its drug
   candidates: LX1031 and LX4211. The Company is also conducting Phase II clinical
   trials of two other drug candidates: LX2931 and LX1032. Lexicon is conducting           Major Industry:
   clinical trials for LX7101, which is in preclinical development.                        Drugs, Cosmetics & Health
                                                                                           Care
                       Stock Chart                                    Officers
                                                                     Chairman
                                                                Dr. Samuel L. Barker       Sub Industry:
                                                                                           Ethical Drug Manufacturers
                                                         President & Chief Executive
                                                              Dr. Arthur T. Sands          Country:
                                                                                           United States
                                                         Executive Vice President &
                                                           Chief Financial Officer         Currency:
                                                               Jeffrey L. Wade             U.S. Dollars

                                                              Vice President Finance       Fiscal Year Ends:
                                                                 James F. Tessmer
                                                                                           December

                                                                                           Employees
                                                                                           290

                                                                                           Exchanges:
                                                                                           NAS

             Stock Price (8/19/2011): 1.20                                                 Share Type:
               Recent stock performance                                                    Common
                  1 Week      -11.8%
                  4 Weeks     -32.6%
                                                                                           Market Capitaliz
								
To top